Literature DB >> 9746797

Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis.

E Graido-Gonzalez1, J C Doherty, E W Bergreen, G Organ, M Telfer, M A McMillen.   

Abstract

The relative contributions of microvascular inflammation and vasomotor dysregulation to the development of acute vaso-occlusive crisis in sickle cell disease have been intensely studied. The present observational study was designed to examine the levels of circulating proinflammatory cytokines, anti-inflammatory cytokines, and vasoactive mediators during and after acute painful crisis. In symptomatic sickle cell patients, plasma levels of endothelin-1 and prostaglandin E2 were elevated during crises compared with healthy African-American controls. These levels had decreased, but not normalized, when patients were seen 1 to 3 weeks after discharge from hospital. Other mediators (tumor necrosis factor alpha [TNFalpha], interleukin-1beta [IL-1beta], IL-6, IL-8, and IL-10) were neither elevated in asymptomatic sickle cell disease nor in acute vaso-occlusive crisis. As a potent long-acting mediator of vasoconstriction and inflammation, endothelin-1 may play a key role in the cycle of ischemia and inflammation that initiates and sustains pain of crisis. The downregulatory effects of prostaglandin E2 on immune cell function may contribute to the increased susceptibility to infection observed in patients with sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746797

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  78 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

Review 2.  The paradox of the neutrophil's role in tissue injury.

Authors:  George B Segel; Marc W Halterman; Marshall A Lichtman
Journal:  J Leukoc Biol       Date:  2010-11-19       Impact factor: 4.962

Review 3.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

Review 4.  Neuronal transient receptor potential (TRP) channels and noxious sensory detection in sickle cell disease.

Authors:  Katelyn E Sadler; Cheryl L Stucky
Journal:  Neurosci Lett       Date:  2018-11-30       Impact factor: 3.046

5.  Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Authors:  Robyn J Barst; Kamal K Mubarak; Roberto F Machado; Kenneth I Ataga; Raymond L Benza; Oswaldo Castro; Robert Naeije; Namita Sood; Paul S Swerdlow; Mariana Hildesheim; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-02-17       Impact factor: 6.998

6.  Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.

Authors:  Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

7.  Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.

Authors:  Terika P Smith; Alyssa M Schlenz; Jeffrey C Schatz; Rangan Maitra; Sarah M Sweitzer
Journal:  Blood Cells Mol Dis       Date:  2014-11-26       Impact factor: 3.039

8.  Effects of nitric oxide and its congeners on sickle red blood cell deformability.

Authors:  Andrea M Belanger; Christian Keggi; Tamir Kanias; Mark T Gladwin; Daniel B Kim-Shapiro
Journal:  Transfusion       Date:  2015-04-23       Impact factor: 3.157

9.  Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.

Authors:  Dhananjay K Kaul; Xiaoqin Zhang; Trisha Dasgupta; Mary E Fabry
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

10.  Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.

Authors:  Caterina P Minniti; Roberto F Machado; Wynona A Coles; Vandana Sachdev; Mark T Gladwin; Gregory J Kato
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.